Opinion
Video
Generalized Myasthenia Gravis Pipeline
Author(s):
Key Takeaways
- Novel therapeutic agents for gMG target specific disease pathways, potentially improving efficacy and safety over traditional treatments.
- Complement inhibitors and FcRn antagonists are among the promising emerging treatments for gMG.
Panelists discuss how emerging agents for generalized myasthenia gravis (gMG) show promise in addressing current treatment gaps, highlighting specific therapies they find particularly exciting for future management of the condition.
Video content above is prompted by the following:
- Which emerging agents in gMG are you excited about?
Related Videos
Related Content
